SIGN UP
LOG IN
News
KURA
17.68
-1.72%
-0.31
Weekly Report: what happened at KURA last week (0408-0412)?
Weekly Report · 4d ago
Kura Oncology to Participate in Stifel Targeted Oncology Forum
Kura Oncology, Inc. Will participate in Stifel 2024 Targeted oncology Forum on April 17, 2024. Troy Wilson, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat. Kura is a clinical-stage biopharmaceutical company committed to precision medicines for the treatment of cancer.
Barchart · 04/10 06:30
Validea Detailed Fundamental Analysis - KURA
NASDAQ · 04/08 20:06
Weekly Report: what happened at KURA last week (0401-0405)?
Weekly Report · 04/08 09:18
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. Granted inducement awards to four new employees to purchase 49,500 shares of common stock on April 1, 2024. The Company is a clinical-stage biopharmaceutical company committed to developing precision medicines for the treatment of cancer.
Barchart · 04/05 06:30
MGNX, SBNY and SLP are among after hour movers
On the Move MGNX, SBNY and SLP are among after hour movers. Signature Bank and Starbucks Corporation are among the losers. Cadiz and Kura Oncology are the biggest losers of the day. The market is down 1% in the last hour.
Seeking Alpha · 04/03 21:24
Weekly Report: what happened at KURA last week (0325-0329)?
Weekly Report · 04/01 09:17
Weekly Report: what happened at KURA last week (0318-0322)?
Weekly Report · 03/25 09:17
Weekly Report: what happened at KURA last week (0311-0315)?
Weekly Report · 03/18 09:17
Weekly Report: what happened at KURA last week (0304-0308)?
Weekly Report · 03/11 09:17
Big Pharma patent cliffs seen fueling oncology M&A this year
Big Pharma patent cliffs seen fueling oncology M&A this year. Around $182B in revenue is at risk over the next four years due to patent expirations. Cantor Fitzgerald sees between five and 17 acquisition deals for oncologists in 2014. The global market for cancer drugs is expected to grow from $180B in 2022 to $323B in 2028.
Seeking Alpha · 03/10 17:08
Kura Oncology Price Target Maintained With a $32.00/Share by HC Wainwright & Co.
Dow Jones · 03/06 17:11
HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
Benzinga · 03/06 17:01
Buy Rating Affirmed: Kura Oncology’s KO-2806 Shows Promising Clinical and Market Potential
TipRanks · 03/06 16:35
Weekly Report: what happened at KURA last week (0226-0301)?
Weekly Report · 03/04 09:17
Press Release: Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. Granted inducement awards to purchase 93,000 shares of common stock to two new employees on March 1, 2024. The stock options were granted under Nasdaq Listing Rule 5635(c)(4) Kura is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
Dow Jones · 03/01 22:00
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. Granted inducement awards to two new employees to purchase 93,000 shares of common stock. The stock options were granted on March 1, 2024. The Company is a clinical-stage biopharmaceutical company. The company is committed to developing precision medicines for the treatment of cancer.
Barchart · 03/01 16:00
Buy Rating for Kura Oncology Amid Strong Q4 Results and Promising Ziftomenib Trials
TipRanks · 03/01 06:02
Kura Oncology Price Target Maintained With a $32.00/Share by HC Wainwright & Co.
Dow Jones · 02/28 18:42
HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
Benzinga · 02/28 18:31
More
Webull provides a variety of real-time KURA stock news. You can receive the latest news about Kura Oncology Inc through multiple platforms. This information may help you make smarter investment decisions.
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.